The eventual tumor recurrence likely resulted from immunoregulatory checkpoints, such as PD-1 on CD8 CTLs and PD-L1 on EG7.OVA cells (Supplementary Fig. 27a), and combination of AlbiCpG + OVA with anti-PD-1 would likely reduce tumor recurrence. This evidence concerns the gene CD8A and neoplasm.